Oryzon Genomics (Spain) Market Value

ORY Stock  EUR 1.56  0.01  0.64%   
Oryzon Genomics' market value is the price at which a share of Oryzon Genomics trades on a public exchange. It measures the collective expectations of Oryzon Genomics SA investors about its performance. Oryzon Genomics is trading at 1.56 as of the 22nd of November 2024, a 0.64% down since the beginning of the trading day. The stock's open price was 1.57.
With this module, you can estimate the performance of a buy and hold strategy of Oryzon Genomics SA and determine expected loss or profit from investing in Oryzon Genomics over a given investment horizon. Check out Oryzon Genomics Correlation, Oryzon Genomics Volatility and Oryzon Genomics Alpha and Beta module to complement your research on Oryzon Genomics.
Symbol

Please note, there is a significant difference between Oryzon Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oryzon Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oryzon Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Oryzon Genomics 'What if' Analysis

In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Oryzon Genomics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Oryzon Genomics.
0.00
10/23/2024
No Change 0.00  0.0 
In 31 days
11/22/2024
0.00
If you would invest  0.00  in Oryzon Genomics on October 23, 2024 and sell it all today you would earn a total of 0.00 from holding Oryzon Genomics SA or generate 0.0% return on investment in Oryzon Genomics over 30 days. Oryzon Genomics is related to or competes with International Consolidated, Neinor Homes, Arteche Lantegi, Melia Hotels, Borges Agricultural, Squirrel Media, and NH Hoteles. Oryzon Genomics S.A., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies to treat o... More

Oryzon Genomics Upside/Downside Indicators

Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Oryzon Genomics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Oryzon Genomics SA upside and downside potential and time the market with a certain degree of confidence.

Oryzon Genomics Market Risk Indicators

Today, many novice investors tend to focus exclusively on investment returns with little concern for Oryzon Genomics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Oryzon Genomics' standard deviation. In reality, there are many statistical measures that can use Oryzon Genomics historical prices to predict the future Oryzon Genomics' volatility.
Hype
Prediction
LowEstimatedHigh
0.051.563.07
Details
Intrinsic
Valuation
LowRealHigh
0.141.653.16
Details
Naive
Forecast
LowNextHigh
0.081.593.10
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.541.691.85
Details

Oryzon Genomics SA Backtested Returns

Oryzon Genomics SA maintains Sharpe Ratio (i.e., Efficiency) of -0.11, which implies the firm had a -0.11% return per unit of risk over the last 3 months. Oryzon Genomics SA exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Oryzon Genomics' Risk Adjusted Performance of (0.09), coefficient of variation of (839.60), and Variance of 2.26 to confirm the risk estimate we provide. The company holds a Beta of 0.23, which implies not very significant fluctuations relative to the market. As returns on the market increase, Oryzon Genomics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Oryzon Genomics is expected to be smaller as well. At this point, Oryzon Genomics SA has a negative expected return of -0.17%. Please make sure to check Oryzon Genomics' treynor ratio, rate of daily change, and the relationship between the information ratio and kurtosis , to decide if Oryzon Genomics SA performance from the past will be repeated at some point in the near future.

Auto-correlation

    
  0.48  

Average predictability

Oryzon Genomics SA has average predictability. Overlapping area represents the amount of predictability between Oryzon Genomics time series from 23rd of October 2024 to 7th of November 2024 and 7th of November 2024 to 22nd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Oryzon Genomics SA price movement. The serial correlation of 0.48 indicates that about 48.0% of current Oryzon Genomics price fluctuation can be explain by its past prices.
Correlation Coefficient0.48
Spearman Rank Test0.57
Residual Average0.0
Price Variance0.0

Oryzon Genomics SA lagged returns against current returns

Autocorrelation, which is Oryzon Genomics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Oryzon Genomics' stock expected returns. We can calculate the autocorrelation of Oryzon Genomics returns to help us make a trade decision. For example, suppose you find that Oryzon Genomics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
   Current and Lagged Values   
       Timeline  

Oryzon Genomics regressed lagged prices vs. current prices

Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Oryzon Genomics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Oryzon Genomics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Oryzon Genomics stock over time.
   Current vs Lagged Prices   
       Timeline  

Oryzon Genomics Lagged Returns

When evaluating Oryzon Genomics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Oryzon Genomics stock have on its future price. Oryzon Genomics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Oryzon Genomics autocorrelation shows the relationship between Oryzon Genomics stock current value and its past values and can show if there is a momentum factor associated with investing in Oryzon Genomics SA.
   Regressed Prices   
       Timeline  

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Oryzon Stock

Oryzon Genomics financial ratios help investors to determine whether Oryzon Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oryzon with respect to the benefits of owning Oryzon Genomics security.